Sonoma Pharmaceuticals manufactures healthcare products using stabilized hypochlorous acid (HOCl), a naturally occurring antimicrobial molecule. Sonoma produces these formulations to treat wound healing, eye hygiene, animal skin care, and dermatological conditions such as eczema and acne. The company manufactures its entire portfolio at a single facility in Mexico. Sonoma primarily generates revenue through a partner-led distribution model, supplying products to global healthcare distributors and retailers like Medline and Compana Pet Brands. These partners sell products under Sonoma brands or custom labels across 55 countries. Sonoma also sells directly to U.S. dermatologists and operates an online consumer store. The company's strategy focuses on expanding its U.S. retail presence in major chains like CVS and Walmart while securing international regulatory approvals to enter new markets. Sonoma positions its HOCl products as safer alternatives to traditional topical steroids and antibiotics because they avoid side effects like skin thinning and bacterial resistance. Growth depends on expanding the scale of distribution partnerships and managing the product mix between prescription, office-dispense, and over-the-counter formats.